Gene therapy : Therapeutic gene causing lymphoma
(2006) In Nature 440(7088). p.1123-1123- Abstract
The development of T-cell leukaemia following the otherwise successful treatment of three patients with X-linked severe combined immune deficiency (X-SCID) in gene-therapy trials using haematopoietic stem cells has led to a re-evaluation of this approach. Using a mouse model for gene therapy of X-SCID, we find that the corrective therapeutic gene IL2RG itself can act as a contributor to the genesis of T-cell lymphomas, with one-third of animals being affected. Gene-therapy trials for X-SCID, which have been based on the assumption that IL2RG is minimally oncogenic, may therefore pose some risk to patients.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/71dd568d-95de-4a30-845e-d9356a4b12a1
- author
- Woods, Niels Bjarne LU ; Bottero, Virginie ; Schmidt, Manfred ; Von Kalle, Christof and Verma, Inder M.
- publishing date
- 2006-04-27
- type
- Contribution to journal
- publication status
- published
- keywords
- Animals, Cell Transformation, Neoplastic/genetics, Clinical Trials as Topic/adverse effects, Disease Models, Animal, Dogs, Genetic Therapy/adverse effects, Hematopoietic Stem Cell Transplantation, Humans, Lymphoma, T-Cell/etiology, Mice, Mice, SCID, Oncogenes/genetics, Receptors, Interleukin-2/genetics, Severe Combined Immunodeficiency/genetics, Time Factors
- in
- Nature
- volume
- 440
- issue
- 7088
- pages
- 1 pages
- publisher
- Nature Publishing Group
- external identifiers
-
- scopus:33646361846
- pmid:16641981
- ISSN
- 0028-0836
- DOI
- 10.1038/4401123a
- language
- English
- LU publication?
- no
- id
- 71dd568d-95de-4a30-845e-d9356a4b12a1
- date added to LUP
- 2017-01-26 08:30:16
- date last changed
- 2024-09-21 08:05:53
@article{71dd568d-95de-4a30-845e-d9356a4b12a1, abstract = {{<p>The development of T-cell leukaemia following the otherwise successful treatment of three patients with X-linked severe combined immune deficiency (X-SCID) in gene-therapy trials using haematopoietic stem cells has led to a re-evaluation of this approach. Using a mouse model for gene therapy of X-SCID, we find that the corrective therapeutic gene IL2RG itself can act as a contributor to the genesis of T-cell lymphomas, with one-third of animals being affected. Gene-therapy trials for X-SCID, which have been based on the assumption that IL2RG is minimally oncogenic, may therefore pose some risk to patients.</p>}}, author = {{Woods, Niels Bjarne and Bottero, Virginie and Schmidt, Manfred and Von Kalle, Christof and Verma, Inder M.}}, issn = {{0028-0836}}, keywords = {{Animals; Cell Transformation, Neoplastic/genetics; Clinical Trials as Topic/adverse effects; Disease Models, Animal; Dogs; Genetic Therapy/adverse effects; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, T-Cell/etiology; Mice; Mice, SCID; Oncogenes/genetics; Receptors, Interleukin-2/genetics; Severe Combined Immunodeficiency/genetics; Time Factors}}, language = {{eng}}, month = {{04}}, number = {{7088}}, pages = {{1123--1123}}, publisher = {{Nature Publishing Group}}, series = {{Nature}}, title = {{Gene therapy : Therapeutic gene causing lymphoma}}, url = {{http://dx.doi.org/10.1038/4401123a}}, doi = {{10.1038/4401123a}}, volume = {{440}}, year = {{2006}}, }